Phreesia, Inc.'s (NYSE:PHR) Chief Financial Officer, Balaji Gandhi, recently sold a portion of his holdings in the company. The transactions, which took place on April 8, 2024, involved the sale of company shares at prices ranging from $22.00 to $23.04.
Gandhi disposed of a total of 7,778 shares of common stock. The bulk of the sale, 7,700 shares, were sold at a weighted average price of $22.6161, while the remaining 78 shares were sold at a weighted average price of $23.0163. The total proceeds from the sales amounted to approximately $175,939.
The sales were conducted under a non-discretionary transaction policy set by Phreesia, Inc., which mandates the sale of shares to cover tax withholding obligations related to the settlement of restricted stock units. This policy is a common practice among public companies to help executives manage tax liabilities associated with the vesting of equity awards.
Following these transactions, Gandhi's ownership in the company stands at 98,178 shares of common stock. The sales were promptly reported to the Securities and Exchange Commission in a Form 4 filing, as required by securities regulations.
Investors often monitor insider transactions such as these for insights into executive confidence and company health. However, such sales are also routinely scheduled and can be part of standard financial planning for individuals in corporate leadership positions.
Phreesia, Inc., headquartered in Wilmington, Delaware, specializes in healthcare software solutions and is recognized for its innovative approach to patient intake management and related services.
InvestingPro Insights
Following the recent insider transactions at Phreesia, Inc. (NYSE:PHR), investors may be seeking additional context to understand the company's financial health and market standing. Insights from InvestingPro reveal a company that operates with a moderate level of debt and has not been profitable over the last twelve months. Moreover, analysts do not anticipate the company will be profitable this year, and it does not pay a dividend to shareholders, which can be important factors for investors considering the stock.
Key metrics from InvestingPro show that Phreesia, Inc. has a market capitalization of $1.31 billion, indicating its size within the healthcare software market. The P/E ratio, a measure of a company's current share price relative to its per-share earnings, stands at -9.20, with an adjusted figure for the last twelve months as of Q4 2024 at -9.96. This negative P/E ratio reflects the company's lack of profitability in the recent period. Additionally, Phreesia has demonstrated substantial revenue growth of 26.84% over the last twelve months as of Q4 2024, which may be a sign of robust business expansion despite the lack of current profitability.
For investors interested in delving deeper into Phreesia's financials and future prospects, there are additional InvestingPro Tips available, which can be found at InvestingPro. To get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, use the coupon code PRONEWS24. There are a total of 4 additional InvestingPro Tips for Phreesia, Inc. that can provide further insights into the company's performance and potential investment opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.